



# Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,  
315-321 Lockhart Road,  
Wan Chai, Hong Kong, China

## ESPS Peer-review Report

**Name of Journal:** World Journal of Hematology

**ESPS Manuscript NO:** 7322

**Title:** Anti-CD20 monoclonal antibodies and associated hepatitis in hematological diseases

**Reviewer code:** 00502976

**Science editor:** Gou, Su-Xin

**Date sent for review:** 2013-11-14 11:34

**Date reviewed:** 2013-11-30 02:08

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

## COMMENTS TO AUTHORS

This review is interesting as it is well documented on the reported hepatitis following the use of the anti-CD20 monoclonal antibody rituximab for treating hematological malignancies. The manuscript needs minor language polishing.



# Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,  
315-321 Lockhart Road,  
Wan Chai, Hong Kong, China

## ESPS Peer-review Report

**Name of Journal:** World Journal of Hematology

**ESPS Manuscript NO:** 7322

**Title:** Anti-CD20 monoclonal antibodies and associated hepatitis in hematological diseases

**Reviewer code:** 02453015

**Science editor:** Gou, Su-Xin

**Date sent for review:** 2013-11-14 11:34

**Date reviewed:** 2013-12-09 12:41

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

## COMMENTS TO AUTHORS

The review manuscript is comprehensive. I recommend adding a figure showing the relationship between anti-CD20 monoclonal antibodies and associated hepatitis, as well as potential ways to avoid or treat such complications.



# Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,  
315-321 Lockhart Road,  
Wan Chai, Hong Kong, China

## ESPS Peer-review Report

**Name of Journal:** World Journal of Hematology

**ESPS Manuscript NO:** 7322

**Title:** Anti-CD20 monoclonal antibodies and associated hepatitis in hematological diseases

**Reviewer code:** 02462691

**Science editor:** Gou, Su-Xin

**Date sent for review:** 2013-11-14 11:34

**Date reviewed:** 2013-12-14 21:43

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

## COMMENTS TO AUTHORS

The review is really about viral hepatitis associated with the use of Anti-CD 20 antibodies, and therefore the title may need change. It was mentioned in table 1 that Ofatumumab did not have an associated hepatitis but a recent FDA alert seems to suggest a risk of HBV with this drug (Mitka M, JAMA 2013; 310:1664). Authors will need to update their literatures, and instead of “none”, maybe it is better to reword as “none reported at the time of review”, since an absence of hepatitis from phase I/II studies does not mean no association. Besides the start time and duration of HBV prophylaxis have not been adequately determined for chemotherapy that involves rituximab, even the choice of agents may not be well-defined, but literature (ref. 101) seems to favour entecavir over lamivudine due to a less breakthrough. I am not entirely sure how much rituximab is really causative of viral hepatitis since literatures seem to have biased against haematological malignancies/chemotherapy but not really autoimmune diseases. Furthermore, the newer Anti-CD 20 did not seem to have this problem (if this is true)? Are there any in-vitro or animal studies that suggest Anti-CD 20 alone induce viral hepatitis?